UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  June 8, 2017
 
Diplomat Pharmacy, Inc.
(Exact Name of Registrant as Specified in its Charter)

 

Michigan
(State or Other Jurisdiction of
Incorporation)	 	001-36677
(Commission File Number)	 	38-2063100
(IRS Employer
Identification No.)	
 
4100 S. Saginaw St.
Flint, Michigan 48507
(Address of Principal Executive Offices)  (Zip Code)
 
(888) 720-4450
(Registrant’s Telephone Number, Including Area Code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
 
o        Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o        Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o        Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o        Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company o
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

 

 
Item 5.07   Submission of Matters to a Vote of Security Holders.
 
At the annual meeting of shareholders of the Company held on June 8, 2017, shareholders elected the two Class III director nominees for three-year terms, ratified the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2017, and approved (on an advisory basis) the Company’s named executive officer compensation.  The annual meeting proposals were described in detail in the Company’s definitive proxy statement filed on April 25, 2017 with the Securities and Exchange Commission.
 
The results of the voting are shown below.
 
Proposal 1 — Election of Directors

Class III Nominees	 	Votes For	 	Votes Withheld	 	Broker Non-Votes	
Regina Benjamin	 	56,500,486	 	544,012	 	6,031,230	
Jeff Park	 	56,502,083	 	542,415	 	6,031,230	
 
Proposal 2—Ratification of the Appointment of Independent Registered Public Accounting Firm

Votes For	 	Votes Against	 	Abstain	
62,523,698	 	480,683	 	71,347	
 
Proposal 3 — Advisory Vote on Named Executive Officer Compensation

Votes For	 	Votes Against	 	Abstain	 	Broker Non-Votes	
56,807,649	 	153,609	 	83,240	 	6,031,230	
 
2 

 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 	Diplomat Pharmacy, Inc.	

 	By:	/s/ Philip R. Hagerman	
 	 	Philip R. Hagerman	
 	 	Chief Financial Officer	
 
Date: June 13, 2017
 
3